Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. (Q45246047)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Laura Vargas-González

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

María T Cáceres-Redondo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Fátima Carrillo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

María J Lama

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Ismael Huertas-Fernández

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Manuel Carballo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

30 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

561-569

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24477490%20AND%20SRC:MED&resulttype=core&format=json

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Duodenal levodopa infusion in Parkinson's disease--long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Population-based norms for the Mini-Mental State Examination by age and educational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Defining mild cognitive impairment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

The heterogeneity of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Weight variation before and after surgery in Parkinson's disease: a noradrenergic modulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Neuropathy as a potential complication of levodopa use in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Role of homocysteine in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7235-1

Combined effect of age and severity on the risk of dementia in Parkinson's disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24477490

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24477490